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Summary Monoclonal antibody (mAb) 83D4 was generated using formol-fixed paraffin-embedded human
breast carcinoma tissue as the immunogen. Previous studies demonstrated that it was reactive with breast
carcinoma tissues, but not with normal breast. The antigen identified by mAb 83D4 was detected, using
ELISA, in MCF7 breast carcinoma cell line membrane extracts, in primary breast and colon carcinoma tissue
extracts and in pleural effusion fluid from patients with metastatic breast cancer. No reactivity with 83D4 was
found in either human milk fat globule membranes or skimmed milk. 83D4 reactive antigen was found to be a
heterogeneous high molecular weight (MW) protein (apparent Mr:300-400 to over 1000 kDa) by sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting. The antigen was
purified from MCF7 cells, breast and colon carcinomas and effusion fluid, by perchloric acid solubilisation
followed by immunoaffinity chromatography with 83D4. The immunopurified antigen from MCF7 cells and
pleural effusion fluid was further analysed by gel filtration and ion-exchange chromatography, which
confirmed the high MW and indicated the charge heterogeneity of the reactive molecules. The 83D4 reactive
antigen strongly bound to wheat-germ agglutinin and weakly to peanut lectin. No binding was found with
lentil lectin or concanavalin A. Antigenic activity was strongly reduced by trypsin and subtilysin digestion and
by treatment with sodium periodate, but it was not affected by neuraminidase. These results imply the
glycoprotein nature of the 83D4-defined antigen and the involvement of carbohydrate, but probably not sialic
acid, in the epitope. Purified 83D4 antigen did not display reactivity for mAb HMFG-1, directed against a
polymorphic epithelial mucin, PEM, using ELISA, but bound mAb CC49 and weakly mAb B72.3, antibodies
which define a tumour associated glycoprotein, TAG-72. Moreover CC49 and 83D4 showed similar reactivity
pattern in immunoblotting assays. A double determinant radioimmunoassay confirmed that 83D4 antigen
carries epitopes for mAb B72.3 and CC49. Competition radioimmunoassays clearly distinguished the 83D4
defined epitope from those recognised by B72.3 and CC49, demonstrating that antibody 83D4 identifies a
unique epitope. It is suggested that the antigens identified by mAb 83D4 and by mAb B72.3 and CC49 may
form part of the same family of carcinoma associated glycoproteins.
Monoclonal antibody (mAb) 83D4 is produced by a murine
hybridoma generated by immunisation with cell suspensions
from a paraffin block of human breast carcinoma tissue.
MAb 83D4 was reactive with three breast cancer cell lines
(MCF7, T47D and H466B) and with breast cancer tissue in
paraffin and frozen sections, but no reactivity with normal
breast epithelium was detected (Pancino et al., 1990a).
Immunohistochemical studies on a large panel of normal and
tumoral human tissues (Charpin et al., manuscript in
preparation) showed mAb 83D4 to be reactive with other
carcinomas including ovarian, endometrial, pancreatic and
colonic adenocarcinomas. In normal tissues, 83D4 reactivity
was limited to colon, stomach and endometrium. A few other
mAb directed against breast-cancer-associated antigens have
been reported which are also not reactive with normal breast
tissues: B72.3, directed against a high molecular weight
(MW) glycoprotein TAG-72 (Colcher et al., 1981 & Thor et
al., 1986); 451B7 and 452F2 recognising a 210 kDa protein
(Frankel et al., 1985); SM-3 raised to the core protein of a
milk mucin, PEM, purified with mAb HMFGI (Burchell et
al., 1987); H23 which was generated by immunisation with a
cellular fraction from T47D breast cancer cell line and is
reactive with a 68 kDa glycoprotein (Keydar et al., 1989). A
cDNA clone isolated using mAb H23 was shown to have
sequences corresponding to a PEM gene domain (Wreschner
et al., 1990). All these mAb were produced using
immunogens different from that used to generate 83D4. Only
mAb B72.3 was reported to have a distribution of reactivity
in human tissues similar to that found with 83D4 (Thor et
al., 1986).
Correspondence: G. Pancino.
Received 6 June 1990; and in revised form I October 1990.
The purpose of the present study was to purify and charac-
terise the antigen identified by mAb 83D4. The antigen was
isolated from different sources, and purified antigen was
analysed by biochemical and immunological methods.
Moreover, the reactivity of mAb HMFG-1 (Taylor-
Papadimitriou et al., 1981) defining the PEM antigen and of
mAb B72.3 and CC49 (Muraro et al., 1988), defining the
TAG-72 antigen, with the 83D4 purified antigen was investi-
gated.
Materials and methods
mAb
IgM mAb 83D4 was generated by immunisation of Balb/c
mice with cell suspensions from formalin-fixed paraffin-
embedded sections of an invasive human breast carcinoma as
described in detail elsewhere (Pancino et al., 1990a). The
antibody was purified from ascitic fluid by dialysis against
demineralised water (Garcia-Gonzales et al., 1988). Precipi-
tated antibody was resuspended in 0.1 M Tris-HCI pH 8, 1 M
NaCl and dialysed against the appropriate buffer.
Control antibodies produced in our laboratory were BIN,
an IgM reactive with a nuclear protein; CA4, an IgM raised
to a human milk cell glycoprotein (Pancino et al., 1991) and
1BE12, an IgM mAb against a breast-cancer-associated
glycoprotein (Pancino et al., 1990b). Culture supernatant
containing mAb HMFG-1 (Taylor-Papadimitriou et al.,
1981) was a generous gift of Dr J. Taylor-Papadimitriou,
Imperial Cancer Research Fund, London, GB. MAbs B72-3
(Colcher et al., 1981) and CC49 (Muraro et al., 1988) raised
to a tumour-associated glycoprotein (TAG-72) were kindly
supplied by Dr J. Schlom, National Cancer Institute,
Bethesda, MD, in the form of ascitic fluids. Purification of
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HMFG-1 concentrated supernatant and of B72.3 and CC49
ascitis was performed using the 'Affi-Gel' protein A Maps-2
kit (Bio-Rad). IgGI immunoglobulins were eluted at pH 6
for B72.3 and CC49 and at pH 5 for HMFG-1 and dialysed
against 0.1 phosphate buffer pH 7.
MAbs 83D4, B72-3 and CC49 were labelled with 1251 using
lodogen by P. Mouly, CIS Bioindustrie, France. Specific
activity was 3.70;LCi Ag-' for 83D4 and 3.251iCipg-g for
B72.3 and CC49.
Antigen sources
The MCF7 breast carcinoma cell line (Soule et al., 1973) was
cultured in Dulbecco's modified Eagle's medium supple-
mented with 10% foetal calf serum, 2 mM L-glutamine,
100IUml' penicillin and 50ligml-' streptomycin. Cell
cytosol and membrane fractions were prepared from MCF7
cells as described (Pancino et al., 1989). Membranes were
extracted with PBS 0.5 NP-40 containing proteases inhibitors
(1 mM PMSF, two kallikrein inhibitor units ml-' bovine
aprotonin).
Breast and colon carcinoma tissues were frozen in liquid
nitrogen. Tissues were homogenised as described (Pancino et
al., 1989) in 20 mM Tris-HCI pH 7.4, 100 mM CaCl, 5 mM
MgCl2, 1% NP-40, 0.5% sodium deoxycholate, 1 mM PMSF
and two kallikrein inhibitor units ml-' bovine aprotonin.
Pleural effusion fluids from patients with metastatic breast
carcinomas were kindly provided by M. Beuzelin, Centre
Rene Hugenin, St Cloud (France).
The protein concentration of each sample was determined
by Lowry's method (Lowry et al., 1951).
Preparation ofhuman milkfat globule membanes (HMFGM)
Crude HMFGM were prepared from fresh human milk as
described (Keenan et al., 1970). After centrifugation at
100,000g for 1 h, the HMFGM pellet was resuspended in
PBS 0.5% NP40, containing protease inhibitors. The protein
concentration was determined by Lowry's method.
Perchloric acid (PCA) fractionation ofthe samples
The MCF7 crude membrane fraction, breast and colon car-
cinoma tissue extracts and pleural effusion fluids were sub-
jected to perchloric acid precipitation at 4°C (0.6 M final
concentration) using the method of Delong and Davidson
(1981). PCA soluble fraction containing 83D4 reactive
material was neutralised with 1.2 M KOH, dialysed against
PBS and concentrated (PCA samples).
Sodium dodecyl sulphate polyacrylamide gel electrophesis
(SDS-PAGE) and immunoblotting
Proteins from PCA samples were precipitated with cold
acetone and the pellet was solubilised in 9.5 M urea, 4%
NP40, 5% ,B-mercaptoethanol and 2% SDS. Samples were
analysed by SDS-PAGE (Laemli, 1970) in 3-10 poly-
acrylamide gels using a stacking gel of 3% acrylamide.
After electrophoresis, proteins were transferred to nitrocel-
lulose paper according to Towbin et al. (1979) at 0.3 amp
overnight in 20 mM Tris HCI pH 8.3, 192 mM glycine, 10%
methanol. The immunological reaction was performed as
described (Pancino et al., 1989). In all experiments, a murine
monoclonal 1gM (BIN or 1BE12) was used as negative con-
trol).
Antigen pur.ification
PCA samples from MCF7 membranes extracts, pleural
effusion fluid, breast carcinoma and colon carcinomas were
loaded onto an 83D4 affinity column. MAb 83D4 (20mg)
was coupled to 10 ml of CNBr-activated Sepharose gel (Phar-
macia) using 0.1 M NaHCO3 binding buffer pH 8.8 contain-
ing 0.5 M NaCl. Uncoupled gel was blocked by 0.2 M glycine.
After overnight incubation at 4°C, the column was washed
with PBS containing 0.5 M NaCl. The bound material was
eluted with 0.2 M glycine-HCl (pH 2.8) containing 0.5 M
NaCl and neutralised with 1 M K2HPO4. Immunoreactivity of
the eluted fractions with 83D4 was assessed by ELISA as
described below. Protein content of the eluate was not
quantifiable by the Lowry method.
For the MCF7 cells and pleural effusion fluid derived
antigen, further purification steps were performed. The
immunopurified fractions containing the antigen were pooled,
dialysed against distilled water and lyophilised. Samples were
solubilised in 20 mM Na2HPO4 (pH 8.5) containing 8 M urea
and applied to a size exclusion Superose-6 HR FPLC gel
filtration column (Pharmacia). Elution was performed using
the same buffer at a flow ratio of 0.5 ml min-'. The
immunoreactivity of the eluted fractions was determined by
ELISA. Fractions containing antigenic activity were applied
to a DEAE mono-Q anion exchange FPLC column (Phar-
macia) equilibrated in 20 mM phosphate buffer (pH 8.5) con-
taining 8 M urea and eluted with a gradient of 0 to 0.5 M
NaCI at a flow rate of 0.8 ml min-'. Eluted fractions were
tested for 83D4 reactivity using ELISA.
ELISA
ELISA was used to assess mAbs reactivity with MCF7 ex-
tracts, breast and colon carcinoma lysates, pleural effusion
fluids, HMFGM and skimmed milk. Samples to be tested
were diluted in 0.1M carbonate-bicarbonate buffer pH 9.6
and dried in microtitre plates (NUNC). Plates were washed
and blocked with 1% gelatin in PBS for 1 h at 37°C. A
three-step method using avidin-biotin peroxidase (IgM or
IgG ABC kit, Vectastain- Vector Laboratories) was used to
reveal mAb binding as described previously (Pancino et al.,
1987). mAb BIN was used as negative control.
Presence of the antigen in the eluates from purification
steps was revealed by the same method, except that samples
were dried in microtitre wells without dilution. mAb IBE12
or BIN were used as negative controls.
Immunopurified and immuno/FPLC(V.) purified antigens
were calibrated by ELISA for 83D4 reactivity and optimal
dilutions were used for subsequent experiments.
All essays were done in duplicate.
Lectin binding assay
83D4 immuno/FPLC(V.) purified antigen from the pleural
effusion fluid was incubated for 2 h at 4°C with 600 jl of
50% (v/v) suspension of Sepharose 4B, Sepharose Con-
canavalin A (CONA), Sepharose Lentil lectin (Lentil),
Sepharose peanut lectin (Peanut) and Sepharose Wheat Germ
agglutinin (WGA). After centrifugation, serial dilutions of
the supernatants were assayed in ELISA for antigenic reac-
tivity with 83D4. After extensive washing, elution of the
bound antigen from Sepharose coupled lectins was performed
with appropriates sugars: 0.5 M a- methylglucopyranoside/ax-
methylmannoside for CONA or Lentil, 0.5 M N-acetyl-
glucosamine for WGA and 0.5 M D-galactose for Peanut.
Recovered materials were tested for antigenic activity by
ELISA.
Periodate and neuraminidase treatment
Periodate oxidation of the immunopurified antigen was per-
formed by the method described by Woodward et al. (1985)
Microtitre wells coated with the antigen were incubated with
NaIO4 (Merck) in 50 mM sodium acetate buffer pH 4.5, at
concentrations ranging from 0.1 to 20 mM for I h at room
temperature in the dark. After washing, plates were
incubated with 1% glycine in PBS for 30min. ELISA with
83D4 was then performed as described above to determine
immunoreactivity.
Immunopurified antigen coated in microtitre plates was
subjected for 1 h at 37°C to enzymatic digestion with
6.25-100 IU ml-' neuraminidase from vibrio cholera (Boeh-
ringer) or from Clostridium perfringens (SIGMA, type X) in392 G. PANCINO
0.05 M acetate buffer pH 5.5, 2 mM CaC12. Control wells were
incubated with the same buffer. After treatment, plates were
washed and ELISA was performed to assess 83D4 reactivity.
Protease digestion
Microplates coated with 83D4 immunopurified antigen were
exposed for I h at 37C to enzymatic treatment with trypsin
(Flow Laboratories) at concentrations ranging from 0.3 to
2.5 mgml-', or subtilysin (SIGMA) at concentrations of
0.125 to 0.5 mgml'1, in 10mM Tris pH8, 2mM CaCI2.
Control wells were incubated with the same buffer. Plates
were then washed and residual antigenic activity was deter-
mined by ELISA.
Double determinant radioimmunoassay (DD-RIA)
A total of 100tl per well of mAb (lOfigml' in 0.1M
carbonate buffer pH 9.6) were incubated in microtitre plates
for 2 h at 37°C and overnight at 4°C. Plates were washed
with PBS 0.1% Tween-20 and blocked with 3% BSA in PBS
for 1 h at 37°C; 100jil of immunopurified antigen at different
dilutions in PBS were added to the wells and incubated for
1 h at 37°C. Control wells without antigen were incubated
with the same buffer. After three washes, 100gtlI of 12511
labelled 83D4 antibody diluted in PBS, 0.1% Tween, 1%
BSA (150,000 c.p.m./well) were added to the wells and
incubated for 2 h at 37°C. Finally after five washes, wells
were cut and bound radioactivity was determined. The 1251I
labelled mAb B72-3 and CC49 were also used as second
antibodies under the same conditions as 83D4. Working
dilutions of purified antigen were determined by DD-RIA
with mAb 83D4 for each sample. All essays were done in
duplicate.
Inhibitory double determinant radioimmunoassay
Plates were coated with mAb 83D4 or with mAb CC49 as
described above for DD-RIA. After blocking with 3% BSA
in PBS, antigen was incubated for 1 h at 37°C. After plate
washing, 50fLd of '25I-labelled antibodies (250 ngml-', corre-
sponding to 150,000 c.p.m. per well) were mixed with increas-
ing concentrations of unlabelled antibodies (ranging from
1 ng ml-' to I05 ngml-' final concentrations) and added in
duplicate to wells. Following 2 h incubation at 37°C, plates
were extensively washed with 0.1% Tween 20 in PBS and
binding of '25I-labelled antibody was measured. Percent
inhibition as compared to a control buffer sample was deter-
mined.
as source of 83D4 reactive antigen in a human tumour of
origin other than breast. Finally, pleural effusion fluid from
patients with metastatic breast carcinomas was tested for
reactivity with 83D4 using ELISA, and a reactive sample was
chosen to characterise the soluble antigen.
Binding of 83D4 antibody to HMFGM extracts and to
skimmed milk was investigated using ELISA. No reactivity
was observed with either component of human milk, while
strong binding was observed with mAb CA4 and with mAb
HMFG1 directed against a human milk fat globule mucin
(Figure 1).
MWdetermination ofantigen
Analysis of NP40 extracts of MCF7 membranes, breast and
colon carcinomas and of pleural effusion fluid was performed
by immunoblotting after SDS-PAGE separation on 3-10%
polyacrylamide gels. Different methods ofsample preparation
for SDS-PAGE were used. The best results were obtained
using the perchloric acid soluble fraction containing 83D4
reactive antigen. Proteins were precipitated with acetone and
solubilised in 9.5 M urea, 4% NP-40, 5% ,-mercaptoethanol
and 2% SDS. 83D4 reactive antigen was identified as a
smear with a range ofapparent MW from the origin ofgel to
about 300 kDa (Figure 2a,d), according to previous results
obtained for MCF7 membrane extracts (Pancino et al.,
1990a). Immunoblotting performed on HMFGM extracts or
skimmed milk failed to detect any reactivity with 83D4
(Figure 2c).
The 83D4 reactive antigen was analysed by 2-D gel electro-
phoresis. Two wide spots were detected by immunoblotting
in the acidic area of the gel (data not shown).
Purification ofthe 83D4 reactive antigen
Since pleural effusion fluid was the most abundant source of
83D4-reactive antigen of breast cancer origin available,
purification of the antigen was performed first from this
material. Immunoreactive material during the different steps
of purification was detected by ELISA. The pleural fluid was
subjected to perchloric acid (PCA) fractionation and 83D4
reactive material remained in the PCA soluble fraction. PCA
soluble material represented about 5% of total proteins. The
acid soluble proteins were then subjected to immunoeffinity
chromatography with immobilised mAb 83D4. For each
experiment 10 mg of PCA sample was loaded on the column.
Proteins content of the eluate was not quantifiable by Lowry
method, but >90% of 83D4 antigenic reactivity was
recovered in eluted fraction, as assessed by ELISA. Eluted
antigen was further purified by size exclusion FPLC in 8 M
Results
Identification ofdifferent sources of83D4 reactive antigen
MAb 83D4 was generated using paraffin-embedded sections
of an invasive breast carcinoma. Flow cytometric analysis of
binding of 83D4 to the surface of human breast carcinoma
cell lines MCF7, H466B and T47D demonstrated that it was
reactive with the three cell lines, the strongest reactivity being
with MCF7 cells (Charpin et al., manuscript in preparation).
Consequently MCF7 cells were chosen as a source for char-
acterising the 83D4 reactive antigen in breast cancer cells in
vitro. ELISA performed on cytolsol and membrane fractions
of MCF7 cells showed that the antigen was present in the
membrane extracts, as expected from previous indirect
immunofluorescence studies which showed membrane stain-
ing (Pancino et al., 1990a). To characterise the antigen ex-
pressed in human tissues, 83D4 reactivity with frozen breast
cancer tissues extracts was tested using ELISA, and a tumour
lysate was chosen among those that showed strong binding
with 83D4. Considering the strong staining of colon
adenocarcinomas by 83D4 in immunoperoxidase studies of
human tissues (Charpin et al., manuscript in preparation), a
colon carcinoma extract binding 83D4 in ELISA was chosen
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Figure 1 Binding of mAbs 83D4 (l10gmlh') (A), HMFGI
(2figml (0) and CA4 (10j.gmlh') (-) at increasing concen-
trations of HFMGM extracts, using ELISA. Antibodies were
diluted in PBS containing 0.5% gelatine and 0.1% Tween.
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Figure 2 Western blot analysis (3-10% polyacrylamide gel) of
83D4 antigen a, b, pleural effusion fluid from a breast cancer
patient. In a, mAb 83D4, in b, mAb BIN; c, skimmed milk with
mAb 83D4, d, e, breast carcinoma extract: in d, mAb 83D4, in e,
mAb BIN, negative control.
urea buffer to ensure complete solubilisation of the proteins.
The immunoreactive material eluted in the void volume of
the column, indicating the high MW of the antigen (Figure 3).
Lower molecular weight proteins, coeluted with the antigen
from the immunoaffinity column, did not bind 83D4. The
reactive fractions were pooled and analysed by anion
exchange FPLC. ELISA performed on the eluted fractions
showed multiple reactive peaks, evidencing the charge
heterogeneity of the antigen (Figure 4). The antigenic activity
profile was similar to the 280 nm absorbance pattern, thus
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Figure 3 Size exclusion chromatography of 83D4 immuno-
affinity purified antigen from a pleural effusion fluid on FPLC
with Superose-6 HR column. Flow rate: 0.5 ml min-'. The eluate
was monitored in absorbance at 280 nm and the collected frac-
tions were tested for 83D4 reactivity in ELISA.
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Figure 4 Anion exchange on FPLC with a mono-Q column of
the pooled 83D4 reactive peak from size exclusion column.
Gradient: 0-0.5 M NaCl. Flow rate of 0.8 ml min '. Eluted frac-
tions were assayed for 83D4 reactivity in ELISA.
indicating that a good antigen purification degree has been
obtained. 83D4 antigen was also isolated from MCF7 memb-
rane extracts, using the same method.
Lectin binding assays
The immuno/FPLC (Vo) purified 83D4 reactive antigen from
the pleural effusion fluid was incubated with 4 Sepharose-
CL4B immobilised lectins with different carbohydrate
specificities: WGA, CONA, Peanut and Lentil. After absorp-
tion, supernatants were tested by ELISA for residual
antigenic reactivity with 83D4 (not shown). No significant
reduction in 83D4 binding compared with the Sepharose
CL4B sample was found with CONA and Lentil, a weak
reduction was observed with PNA while WGA incubation
abolished sample reactivity. After elution with appropriate
carbohydrates no antigenic material was found using ELISA
in eluates from CONA and Lentil and weak 83D4 reactivity
was observed with Peanut eluate. Conversely 83D4 reactivity
was completely recovered in eluate from WGA (Figure 5).
Biochemical analysis of83D4 reactive antigen
The immunopurified antigen was subjected to proteolytic
digestion with trypsin and subtilysin, resulting in a sharp
reduction in 83D4 binding. Figure 6a shows that trypsin
gradually reduced 83D4 reactivity up to 90% at a
2.5 mgml' concentration, while subtilysin had already
abolished antibody binding at the first concentration tested
(0.125 mgml-').
To determine whether carbohydrate structures take part in
the 83D4 antigenic determination, the antigen was subjected
to sodium periodate oxidation. Figure 6b shows that 83D4
binding was reduced after Na periodate treatment, up to an
85% reduction at 20 mM metaperiodate concentrations. In
contrast, antigenic reactivity was not affected by treatment
with Neuraminidase from Vibrio cholera or from Clostridium
perfringens (Figure 6c).
Repeated epitope expression of83D4 reactive antigen
Immunoaffinity-purified antigen was tested for its reactivity
in a double determinant radioimmunoassay. Antigen purified
from breast cancer pleural effusion and colon carcinoma394 G. PANCINO
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Figure 5 Lectin binding to 83D4 immuno/FPLC (Vo) purified
antigen from a pleural effusion fluid. After incubation with
different lectins (WGA (*), CONA (A), Lentil (O), Peanut
(U)), bound antigen was eluted with appropriate sugars as des-
cribed in 'Materials and methods'. Recovered antigenic activity
was assessed by ELISA with mAb 83D4.
tissue was incubated in microplates coated with mAb 83D4;
'5I-labelled 83D4 antibody binding was subsequently
measured on fixed antigen. Significant binding of the
radiolabelled antibody (Figure 7a,b) indicated that the
antigen expressed multiple 83D4 reactive epitopes.
HMFGJ reactivity with the 83D4 defined antigen
To investigate the expression of HMFG1 epitope on 83D4
defined antigen an ELISA was performed using the immuno/
FPLC (Vo) purified 83D4 antigen from MCF7 membrane
extracts. No significant reactivity was detected with HMFG1,
which conversely bound to the MCF7 PCA sample from
which antigen had been isolated (Figure 8). Immunoblotting
of MCF7 PCA sample and purified antigen confirmed these
results (not shown).
B72-3 and CC49 reactivity with 83D4 defined antigen
MAb B72-3 directed against a high MW carcinoma-
associated mucin TAG-72, and the second-generation mAb
CC49 raised to purified TAG-72 were tested for reactivity to
the 83D4 defined antigen. ELISA assays on the immuno/
FPLC (Vo) purified 83D4 antigen from MCF7 membranes or
pleural effusion fluid showed CC49 binding to the antigen,
while very weak reactivity was detected with B72-3 (not
shown). Moreover FPLC filtration fractions of immuno-
purified 83D4 antigen were tested for reactivity with mAbs
83D4 and CC49: antigenic activity was found in the Vo
fraction as expected, while low molecular species were
unreactive with both antibodies. Immunoblotting of PCA
sample from a pleural effusion fluid was then performed to
compare reactivity patterns of mAbs 83D4 and CC49. Reac-
tive bands of high MW with similar electrophoretic mobility
were detected by the two antibodies (Figure 9). In further
RIA experiments immunopurified antigens were used. 83D4
antigens from pleural effusion fluid, breast carcinoma and
colon carcinoma extracts were tested in a double determinant
RIA for binding to mAb B72-3 and CC49. Table I shows
that 125I-labelled B72-3 and CC49 displayed binding with
83D4 antigen fixed on mAb 83D4-coated plates with
differential reactivity depending on the source of the antigen.
B72-3 showed weak binding to the 83D4 defined antigen
immunopurified from pleural effusion, colon or breast car-
cinoma. CC49 exhibited weak reactivity with breast car-
cinoma or pleural effusion antigen, but a strong reaction with
the colon carcinoma antigen.
83D4, B72-3 and CC49 were analysed in a inhibitory
double determinant RIA on pleural effusion and colon car-
cinoma immunopurified antigens in order to study the rela-
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Figure 6a Effect of proteolytic digestion of 83D4 immuno-
purified antigen from a pleural effusion fluid on 83D4 reactivity.
Antigen coated on microplates was incubated with increasing
concentrations of trypsin (0) or subtilysin (U) as described in
'Materials and methods'. After treatment, 83D4 binding was
determined by ELISA. b, Effect of Na-metaperiodate treatment
on 83D4 reactivity with the immunopurified antigen from a
pleural effusion. Antigen absorbed on a microplate was exposed
to increasing concentrations of periodate as described in
'Materials and methods'. After treatment, 83D4 reactivity was
tested by ELISA. c, Neuraminidase digestion of 83D4 defined
antigen immunopurified from a pleural effusion. Antigen
absorbed on a microplate was treated with increasing concen-
trations of neuraminidase from Vibrio cholera (0) or from Clost-
ridium perfringens (U). After digestion, 83D4 reactivity was
tested by ELISA.
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Figure 7 Repeated epitope expression of 83D4 defined antigen.
Double determinant-RIA was performed as described in
'Materials and methods' on serial dilutions of antigen
immunopurified from a, a breast cancer pleural effusion fluid or
b, a colon carcinoma extract.
tionship between antigenic determinants of these antibodies.
Similar results were found with antigens of both origins. No
competition with 83D4 was shown by mAb B72-3 (results
not shown). CC49 competed at 35% for the highest concen-
trations (50 and 1001g ml-' of CC49) for the colon-cancer-
derived antigen (Figure 10a). In the reciprocal mAb CC49
competition RIA, 83D4 competed at 65% for maximal con-
centrations (Figure 10b).
Discussion
MAb 83D4 was produced by immunising mice with paraffin
sections of an invasive breast carcinoma. It has previously
been shown to react with both fixed and paraffin-embedded
and frozen breast carcinoma tissues (Pancino et al., 1990a).
No reactivity was detected with normal breast. These studies
indicated that 83D4 identifies a native antigen not affected by
fixation and paraffin embedding procedures, and that the
antigen is well expressed in breast cancer, but is absent in
normal mammary epithelium.
In the present work, the antigen was detected in MCF7
breast cancer cell line membrane extracts, in primary breast
carcinoma and in colon carcinoma extracts. The antigen was
also detected and then isolated from a pleural effusion fluid
of patients with metastatic breast carcinoma, indicating that
it can be released in soluble form from breast cancer cells.
No detectable expression of the antigen was found in human
milk components. Immunoblotting analysis showed that
83D4 epitopes are carried by heterogeneous acidic proteins of
Figure 8 HMFG1 reactivity with 83D4 antigen; a, ELISA on
immuno/FPLC (Vo) purified 83D4 antigen from MCF7 mem-
branes extract; b, ELISA on PCA fraction of MCF7 membranes
extract from which 83D4 antigen used in a, was isolated.
(HMFG1 (0), 83D4 (A), and BIN (A). MAbs concentration:
Iofig ml-').
high MW (>300 kDa). The antigen, soluble in PCA, was
purified using immunoaffinity chromatography, subsequent
gel filtration and anion exchange chromatography. The
83D4-reactive molecules, solubilised in 8M urea buffer, were
eluted in the void volume of a Superose 6 FPLC gel column
and resolved in multiple peaks by anion exchange FPLC.
The immunopurified 83D4-reactive antigen bound to WGA,
specific for N-acetyl D-glucosamine and sialic acid, and
weaker to Peanut lectin. No binding was observed with other
lectins (CONA, Lentil). The antigenic activity was affected by
protease digestion with trypsin and subtilysin. These findings
taken together indicate that the antigen is composed of
heterogeneous acidic glycoproteins of high MW and that the
carbohydrate component contains N-acetyl glucosamine and/
or sialic acid. The biochemical nature of the 83D4 reactive
epitope was further analysed by neuraminidase digestion and
sodium periodate oxidation. The gradual decrease in 83D4
binding upon periodate oxidation from 0.1 mM to 20 mM
periodate concentrations suggests that the epitope defined by
83D4 involves carbohydrates.
However the antigen was resistant to digestion with
neuraminidase from Vibrio cholera and Clostridium per-
fringens, suggesting that sialic acid is not required for binding
of 83D4.
We looked for a relationship of 83D4 defined antigen with
other breast cancer associated high MW glycoproteins
defined by murine mAbs. A well known 'immunodominant'
antigenic family is a mucin found in human milk, breast
cancer and in other tumoral and normal epithelia, and
identified by several mAb (Taylor-Papadimitriou et al., 1981;
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Figure 9 Immunoblotting of PCA sample from a pleural
effusion fluid, with mAbs 83D4 (lane a) and CC49 (lane b). Lane
c: mAb lBE12, negative control.
Table I Reactivity of mAb 83D4 and mAbs B72-3 and CC49 with
83D4 defined antigen purified from three different sources using
S-RIA
Antigen source 83D4* B72-3 CC49
Pleural effusion 6172** 1115 2819
Breast carcinoma 13315 588 2340
Colon carcinoma 16214 1259 20950
Buffer controls: 83D4 504 c.p.m., B72-3 199 c.p.m., CC49
229 c.p.m.; *specific activity of '251-labelled antibodies: 83D4:
3.70fiCigg-g; B72-3 and CC49: 3.25 ACigg-'; **c.p.m. bound.
Ashall et al., 1982; Hilkens et al., 1984; Papsidero et al.,
1984; Sekine et al., 1985; Price et al., 1986; Linsley et al.,
1986; Stacker et al., 1989). cDNA clones coding for the core
protein of this mucin, termed Polymorphic Epithelial Mucin
(PEM), were recently isolated and the amino acid sequence
was fully determined (Gendler et al., 1988 and 1990). We
used mAb HMFG1, which defines the PEM antigen, to study
the relationship with 83D4 antigen: no binding of HMFG1
to 83D4 purified antigen could be detected by ELISA and
immunoblotting.
The glycoprotein nature of the antigen recognised by
83D4, its binding to WGA, its apparent MW and hetero-
geneity and its selective reactivity for breast tumours vs
normal breast tissue are similar to the characteristics of a
pancarcinoma-associated glycoprotein TAG-72 (Johnson et
al., 1986) defined by mAb B72.3, generated using a mem-
brane preparation from a mammary carcinoma metastasis
(Colcher et al., 1981). It was thus important to determine
whether a relationship of 83D4 antigen to TAG-72 exists.
MAbs B72.3 and colon cancer-purified TAG-72 second
generation mAb CC49 (Muraro et al., 1988) were used for
this study. 83D4 immuno/FPLC (Vo) purified antigen bound
the two antibodies in ELISA and immunoblotting showed
similar reactivity patterns of 83D4 and CC49 antibodies.
Since the reactivity of mAb B72.3 and CC49 has been shown
to vary with different tumour extracts of breast and colon
carcinomas (Muraro et al., 1988), three different sources of
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Figure 10 Inhibitory double determinant-RIA using '251-labelled
mAb 83D4 a, and '251-labelled mAb CC49, b. Purified mAb 83D4
and CC49 were used as competitors for binding of the
radiolabelled mAb with the 83D4 defined antigen purified from a
colon carcinoma extract as described in 'Materials and methods'.
Concentrations of competitor antibody are expressed in ng ml-'
a, 83D4 (0), CC49 (M), b, CC49 (0), 83D4 (M).
83D4 defined antigen were used for further cross-reactivity
studies. Differential binding of mAb B72.3 and CC49 to
83D4 defined antigen was found using the antigen purified
from pleural effusion fluid, breast carcinoma or colon car-
cinoma. B72.3 bound weakly to effusion fluid and colon-
carcinoma-derived antigens and very weakly to the breast-
carcinoma-derived antigen, while CC49 bound weakly to
antigens of breast cancer origin, but stronger to the colon-
cancer-derived antigen. These results indicate that 83D4
defined antigen carries epitopes reactive with B72.3 and
CC49, which may vary quantitatively in different sources,
CC49 epitope being most expressed in colon carcinoma. MAb
B72.3 and CC49 both react with the carbohydrate epitopes
(Johnson et al., 1986; Kjeldsen et al., 1988; Sheer et al., 1988)
and the 83D4 epitope also appears to involve sugar moieties.
A competition RIA showed that B72.3 did not compete with
83D4, and that CC49 only partially inhibited 83D4 binding
to its antigen. The failure of B72.3 to compete with 83D4
could be expected, since the B72.3-reactive epitope has been
shown to be a sialosyl-Tn structure (Kjeldsen et al., 1988)
sensitive to neuraminidase digestion (Kjelden et al., 1988 &
Johnson et al., 1986), while the 83D4 epitope was not
affected by neuroaminidase treatment. There are several pos-
sible interpretations for the partial competition between
CC49 and 83D4: the two epitopes may be distinct, but in
physical proximity to each other; they may be only partially
overlapping; or partial inhibition may have resulted from
conformational changes induced by antibody binding. It is
possible that conformational changes in the antigen molecule
or steric hindrance of the binding site caused by 83D4 IgM
immunoglobulin may partially account for the asymmetricBREAST-CANCER ASSOCIATED GLYCOPROTEIN 397
pattern of cross-competition between IgM 83D4 and IgGI
CC49 (CC49, at the highest concentrations, inhibited 35% of
83D4 binding to antigen; 83D4 inhibited 65% of CC49 bin-
ding in reciprocal competition RIA).
In the summary, the results reported above suggest that
the antigen identified by 83D4 shares common antigenic
activity with the TAG-72 antigen identified by B72.3 and
CC49, but expression of reactive epitopes varies with the
antigen source. The antigenic determinant identified by 83D4
appears to be different from those defined by B72.3 and
CC49. The relationship shown to exist between the 83D4
reactive antigen and the TAG-72 antigen is suggestive of the
hypothesis that they may belong to the same family of
related, high MW tumour-associated glycoproteins. The
difference in immunoreactivity found with 83D4 in com-
parison with B72.3 or CC49 may result from expression of a
different number of carbohydrate epitopes on the same pro-
tein molecule, caused by varying degrees of glycosylation.
However, it cannot be excluded that differential reactivity
may be due to different proteins carrying the epitopes on the
oligosaccharide side chains. It is worth noting that
hybridoma-secreting mAb 83D4 was generated in a complete-
ly different way from B72.3 and CC49. Epitope analysis and
mapping of 83D4 defined antigen and TAG-72 antigen, as
well as cloning of coding genes, would clearly define their
relationship and indicate whether these molecules constitute a
new family ofcarcinoma-associated glycoprotein antigens. At
present, it is known that mAb B72.3 identifies a sialyl-Tn
epitope, and CC49 has been claimed to react with other
oligosaccharides; this study demonstrates that 83D4 identifies
a novel epitope and that sugar moieties take part in it. A
number of tumour-associated glycoprotein carbohydrate
epitopes have been detected by mAb, and some of them have
been characterised, including antigen reactive with the mAb
19-9 directed to a sialyl-Lea carbohydrate chain carried on a
gastrointestinal-cancer-associated mucin (Magnani et al.,
1983), and the Tn antigen identified by mAb NCC-LU-35
and NCC-LU-81 raised against squamous lung carcinomas
(Hirohashi et al., 1985). Aberrant glycosylation of glyco-
protein antigens is a common phenomenon in human cancers
(reviewed in Hakomori, 1989). Studies to define the structure
of the 83D4 reactive epitope and its function are now
required to elucidate its relationship with oncogenic trans-
formation.
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